Company news
Atossa Therapeutics, Inc. news in 2019
Atossa Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
December 18, 2019
Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019
December 4, 2019
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update
November 12, 2019
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology
October 15, 2019
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen
September 29, 2019